Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 7/20 | 0.36 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1814754 | 0.86 | ENPP2 (0.42) | ENPP2GRM5GRM1GRM2PRMT5 | |
| SCHEMBL1824466 | 0.83 | IKZF2 (0.40) | GRM5GRM1PRMT5IKZF2MAOA | |
| SCHEMBL6875893 | 0.77 | MCHR1 (0.38) | ENPP2GRM5GRM1MAOAMCHR1 | |
| SCHEMBL6877141 | 0.77 | ENPP2 (0.39) | ENPP2GRM5GRM1MAOAMCHR1 | |
| SCHEMBL1817239 | 0.75 | ENPP2 (0.39) | ENPP2GRM5GRM1MAOAMCHR1 | |
| SCHEMBL6876204 | 0.74 | GRM5 (0.39) | ENPP2GRM5GRM1MAOAMCHR1 | |
| SCHEMBL6874779 | 0.72 | ENPP2 (0.38) | ENPP2GRM5GRM1MAOAMCHR1 | |
| SCHEMBL6874788 | 0.72 | CYP2C9 (0.41) | ENPP2GRM5GRM1MAOAMCHR1 | |
| SCHEMBL1816706 | 0.72 | CYP2C9 (0.37) | GRM5GRM1MAOAMCHR1LIPG | |
| SCHEMBL1819932 | 0.72 | ENPP2 (0.41) | ENPP2GRM5GRM1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507521-B2 | Heterocyclic derivatives | Merck Sharp + Dohme B.V. (NL) | 2013-08-13 | — | — | US | claimed |
| US-20120220622-A1 | HETEROCYCLIC DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2012-08-30 | — | — | US | claimed |
| US-8507521-B2 | Heterocyclic derivatives | Merck Sharp + Dohme B.V. (NL) | 2013-08-13 | — | — | US | disclosed |
| US-8507521-B2 | Heterocyclic derivatives | Merck Sharp + Dohme B.V. (NL) | 2013-08-13 | — | — | US | disclosed |
| US-8507521-B2 | Heterocyclic derivatives | Merck Sharp + Dohme B.V. (NL) | 2013-08-13 | — | — | US | disclosed |
| EP-2496569-A2 | HETEROCYCLIC DERIVATIVES | MSD Oss B.V. (NL) | 2012-09-12 | — | — | EP | disclosed |
| US-20120220622-A1 | HETEROCYCLIC DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2012-08-30 | — | — | US | disclosed |
| US-20120220622-A1 | HETEROCYCLIC DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2012-08-30 | — | — | US | disclosed |
| US-20120220622-A1 | HETEROCYCLIC DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2012-08-30 | — | — | US | disclosed |
| WO-2011051490-A2 | HETEROCYCLIC DERIVATIVES | N.V. ORGANON (NL) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011051490-A2 | HETEROCYCLIC DERIVATIVES | N.V. ORGANON (NL) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220622-A1 | HETEROCYCLIC DERIVATIVES | GRIN2C, GRIN3A, GRIN2D | ENPP2 2659/4885GRM5 5/4885GRM1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.